Payment overview · 2025
General Payments
$738.89
50 reported records · 12 companies
Healthcare provider profile · identity verified
Lorena H Tan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIVERMORE, CA · NPI 1417957697
Verified facts
What the public records show
CMS Open Payments records show Lorena H Tan, MD received $738.89 in general payments during 2025 across 50 reported records.
GlaxoSmithKline, LLC. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $191.29 | 25.9% | 12 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $126.75 | 17.1% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.68 | 13.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.28 | 11.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.32 | 9.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.09 | 5.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.68 | 4.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.17 | 3.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.96 | 2.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.75 | 2.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.24 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.68 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $738.89 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $155.56 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $83.28 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.48 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.48 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $44.20 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.73 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
58 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 686 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 200 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 588 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 174 |
| Losartan Potassium | Losartan Potassium | 490 | 143 |
| Lisinopril | Lisinopril | 364 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 82 |
| Metformin Hcl Er | Metformin Hcl | 260 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 126 |
| Gabapentin | Gabapentin | 235 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 74 |
| Azithromycin | Azithromycin | 227 | 187 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 65 |
| Metformin Hcl | Metformin Hcl | 209 | 63 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 199 | 71 |
| Cephalexin | Cephalexin | 165 | 123 |
| Potassium Chloride | Potassium Chloride | 163 | 41 |
| Atenolol | Atenolol | 135 | 41 |
| Trazodone Hcl | Trazodone Hcl | 126 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 37 |
| Simvastatin | Simvastatin | 118 | 33 |
| Allopurinol | Allopurinol | 115 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 37 |
| Omeprazole | Omeprazole | 106 | 35 |
| Methylprednisolone | Methylprednisolone | 105 | 82 |
| Furosemide | Furosemide | 99 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 30 |
| Ezetimibe | Ezetimibe | 91 | 34 |
| Montelukast Sodium | Montelukast Sodium | 87 | 29 |
| Carvedilol | Carvedilol | 84 | 28 |
| Jardiance | Empagliflozin | 79 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 21 |
| Sertraline Hcl | Sertraline Hcl | 76 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 24 |
| Eliquis | Apixaban | 72 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 59 |
| Bupropion Xl | Bupropion Hcl | 69 | 28 |
| Xarelto | Rivaroxaban | 69 | 16 |
| Meloxicam | Meloxicam | 68 | 29 |
| Synthroid | Levothyroxine Sodium | 68 | 21 |
| Valacyclovir | Valacyclovir Hcl | 67 | 32 |
| Farxiga | Dapagliflozin Propanediol | 66 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 49 |
| Paxlovid | Nirmatrelvir/Ritonavir | 58 | 57 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 17 |
| Lovastatin | Lovastatin | 54 | 12 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 23 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Famotidine | Famotidine | 47 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 37 |
| Glimepiride | Glimepiride | 44 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 16 |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Glipizide | Glipizide | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 21 |
| Levoxyl | Levothyroxine Sodium | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Valsartan | Valsartan | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 21 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | 11 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 12 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 20 | suppressed |
| Prolia | Denosumab | 20 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Prednisone | Prednisone | 19 | 17 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 14 |
| Temazepam | Temazepam | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | 11 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Anastrozole | Anastrozole | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $738.89 · 50 records | GlaxoSmithKline, LLC. | CONTRAVE, Cologuard Collection Kit, FARXIGA, Kerendia, Leqembi, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REXULTI, SHINGRIX, Symbravo, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error